Lazar David E.
Transaction: 10/21/2025
SELL
Change
-39,925
Price
Not reported
Filing
01/29/2026
Type
SELL
NovaBay Pharmaceuticals, Inc.
NBY • Biotechnology
Extraordinary move
NBY-24.62%
vs. previous close $1.95
$1.47
▼ -0.48 (-24.62%)
Current price
EarningsLatest report: Mar 31, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$243.58M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Healthy liquidity · 7.6Negative growth trendWeak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: Apr 1, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.47
Change-24.62%
Shares Out165.71M
Market Cap$243.58M
Enterprise Value$225.64M
52W Range1.11 - 99.75
Beta0.16
P/E0.47
P/S98.89
P/B1.75
P/FCF-2.84
EV/Sales91.61
Price$1.47
Change-24.62%
Shares Out165.71M
Market Cap$243.58M
Enterprise Value$225.64M
52W Range1.11 - 99.75
Beta0.16
P/E0.47
P/S98.89
P/B1.75
P/FCF-2.84
EV/Sales91.61
EV/EBITDA-43.53
EV/FCF-2.63
Earnings Yield214.55%
FCF Yield-35.24%
Dividend Yield278.76%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq-0.03
Current Ratio7.60
Quick Ratio7.60
Volume86.83K
Avg Volume552.07K
EPS Surprise22.23
Investment DNA
How strong this company looks for long-term investors
33
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
50/100
Why this score▼
Healthy liquidity · 7.6Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
70/100
Bullish
Bullish
2
Hold
3
Bearish
0
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Lazar David E.
Transaction: 10/21/2025
BUY
Change
+6,388,000
Price
Not reported
Filing
01/29/2026
Type
BUY
Kazley Michael John
Transaction: 10/21/2025
BUY
Change
+56,806,080
Price
Not reported
Filing
11/03/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Lazar David E. | SELL | -39,925 | Not reported | 10/21/2025 | 01/29/2026 |
| Lazar David E. | BUY | +6,388,000 | Not reported | 10/21/2025 | 01/29/2026 |
| Kazley Michael John | BUY | +56,806,080 | Not reported | 10/21/2025 | 11/03/2025 |
| R01 Fund LP | BUY | +56,806,080 | Not reported | 10/21/2025 | 11/03/2025 |
| Framework Ventures IV L.P. | BUY | +56,806,080 | Not reported | 10/21/2025 | 11/03/2025 |
| Kazley Michael John | BUY | +2,702,703 | $0.01 | 10/16/2025 | 11/03/2025 |
| R01 Fund LP | BUY | +2,702,703 | $0.01 | 10/16/2025 | 11/03/2025 |
| Framework Ventures IV L.P. | BUY | +2,702,703 | $0.01 | 10/16/2025 | 11/03/2025 |
| R01 Fund LP | BUY | +134,375 | Not reported | 10/16/2025 | 10/20/2025 |
| R01 Fund LP | OTHER | +1,164,117 | Not reported | 10/16/2025 | 10/20/2025 |
| Framework Ventures IV L.P. | BUY | +134,375 | Not reported | 10/16/2025 | 10/20/2025 |
| Framework Ventures IV L.P. | OTHER | +1,164,117 | Not reported | 10/16/2025 | 10/20/2025 |
| Kazley Michael John | BUY | +134,375 | Not reported | 10/16/2025 | 10/20/2025 |
| Kazley Michael John | OTHER | +1,164,117 | Not reported | 10/16/2025 | 10/20/2025 |
| Lazar David E. | SELL | -441,325 | Not reported | 10/16/2025 | 10/17/2025 |
| Lazar David E. | OTHER | 0 | Not reported | 08/19/2025 | 08/26/2025 |
| Lazar David E. | OTHER | +77,000,000 | Not reported | 08/19/2025 | 08/26/2025 |
| POPLAR POINT CAPITAL PARTNERS LP | BUY | +300 | $0.47 | 04/08/2025 | 04/15/2025 |
| POPLAR POINT CAPITAL PARTNERS LP | BUY | +4,538 | $0.52 | 04/04/2025 | 04/15/2025 |
| POPLAR POINT CAPITAL PARTNERS LP | BUY | +22,976 | $0.56 | 04/03/2025 | 04/15/2025 |